

Diastereoselective Syntheses of (2*R*,3*R*,5*R*)- and (2*S*,3*S*,5*S*)-3-Hydroxy-5-methyl-2-pyrrolidinecarboxylic Acid as a Component of Actinomycin Z₁

Ken-ichi Tanaka* and Hiroyuki Sawanishi

Faculty of Pharmaceutical Science, Hokuriku University, Ho-3, Kanagawa-machi, Kanazawa 920-1181, Japan

Received 25 May 1998; accepted 16 June 1998

Abstract: A novel diastereoselective syntheses of both (2*R*,3*R*,5*R*)-**1** and its enantiomer (2*S*,3*S*,5*S*)-**1** were accomplished by employing *trans*-selective nucleophilic addition of cyanide to 3-benzoyloxy-*N*-acyliminium ions as the key step, starting from *trans*-4-hydroxy-*L*-proline.

© 1998 Elsevier Science Ltd. All rights reserved.

Keywords: Unusual amino acids; Asymmetric synthesis; Stereoselection; *N*-Acyliminium ion; Lactam synthesis.

An unusual amino acid, 3-hydroxy-5-methyl-2-pyrrolidinecarboxylic acid (**1**) was found as a minor component of a peptide antibiotic actinomycin Z₁ produced by *Streptomyces fradiae*.¹ After the syntheses of the four diastereoisomers of **1**, the relative stereochemistry of this compound was elucidated to be 2,3-*trans* and 2,5-*cis* configuration based on analyses of ¹H-NMR coupling constants by Mauger *et al.*² The absolute configuration (2*S*,3*S*,5*S* or 2*R*,3*R*,5*R*) and biological activities of the natural amino acid (**1**), however, remain unknown due to their sort supply from natural sources. Consequently, the development of efficient and stereoselective methods to produce such amino acid in an enantiomerically pure form is crucial. To our knowledge, only two reports on the synthesis of **1** are found in literature, one of the four racemic diastereoisomers,² and another of the optically active forms,³ which were prepared by [3+2] dipolar cycloaddition starting from *L*-vinylglycine.





Figure 1



Scheme 1

In continuing our studies in the asymmetric synthesis of novel unusual α -amino acids containing pyrrolidine ring,⁴ we report herein the novel diastereoselective syntheses of both (2*R*, 3*R*, 5*R*)-**1** and its enantiomer (2*S*,3*S*,5*S*)-**1** starting from *trans*-4-hydroxy-*L*-proline. Our synthetic strategy for (2*R*, 3*R*, 5*R*)-**1** is illustrated in Scheme 1. Thus, the carboxyl group of α -amino acid moiety of (*R*)-configuration can be


obtained through the *trans*-nucleophilic addition of cyanide anion to the C3-substituent group of *N*-acyliminium ion intermediate **B** derived from homochiral lactam **C**, followed by acidic hydrolysis of both cyano and protecting groups. In connection with the reaction of *N*-acylpyrrolidine 2-iminium ions,⁵ Wistrand has reported that the stereoselectivity of nucleophilic addition of cyanide anion to the *N*,*O*-diprotected 3-hydroxypyrrolidine-2-iminium ions can be controlled by the nature of the *O*-protecting group at the C3-position.^{5a} On the other hand, Shono and Matsumura have reported that the degree of stereoselectivity depends on both the steric bulkiness of *N*-protecting groups and the nature of the substituents of the pyrrolidine ring.⁶ We therefore investigated the reaction of *N*-acyliminium ion **B** with different *N*,*O*-diprotecting groups in order to enhance the desired *trans* selectivity.

Results and Discussion

1. Synthesis of (2*R*,3*R*,5*R*)-1

First, for the synthesis of (2*R*, 3*R*, 5*R*)-1, nucleophilic addition of cyanide to *N*-acyliminium ion **6** with sterically bulky *O*-*tert*-butyldimethylsilyl (*O*-TBS) group at C3-position was examined as shown in **Scheme 2**. Thus, ruthenium tetroxide (RuO₄) oxidation⁷ of **2** easily prepared from *trans*-4-hydroxy-*L*-proline,⁸ followed by chemoselective partial reduction of the resulting lactam **3** with LiEt₃BH in tetrahydrofuran at -78°C led to a diastereomeric mixture of hemiaminal **4** and subsequent treatment of **4** with pyridinium *p*-toluenesulfonate (PPTS) in methanol gave the corresponding 2-methoxypyrrolidine **5** as a mixture of diastereoisomers. **5** was directly converted into 2-cyanopyrrolidines (**7** and **8**) by treatment with trimethylsilyl cyanide (TMSCN) in the presence of boron trifluoride etherate in dichloromethane at -78°C^{5a,d} and the desired 2,3-*trans*-2-cyanopyrrolidine **7** as a minor product and the undesirable its *cis*-isomer **8** as a major product were isolated in a ratio of 30:70 in 84% combined yield. 2-Cyanopyrrolidines **7** and **8** could be cleanly separated by column chromatography on silica gel.


The stereochemistries of the newly formed stereogenic centers at C2 position of these isomers **7** and **8** were assigned by NOE experiments, as indicated in **Scheme 2**. Thus, for the compound **7**, irradiation of the C5-H resulted in enhancement of the signal due to the C2-H and irradiation of the C3-H gave no enhancement of the signal due to the C2-H. For the compound **8**, irradiation of the C3-H resulted in enhancement of the signal due to the C2-H. Accordingly, the C2-H and C3-H in **7** and **8** were assigned to have *trans*- and *cis*-configurations, respectively.



Reagents and Conditions : a) RuO₄ · H₂O, 10% aq. NaIO₄, AcOEt, 88% b) LiEt₃BH, THF, -78°C c) PPTS, MeOH, r.t., 75%, 2 steps d) TMSCN, BF₃ · Et₂O, CH₂Cl₂, -78°C, 84% (7:8=30:70)

Scheme 2

Next, we decided to exchange both the *N*- and *O*-protecting groups of the intermediate **6** and investigated stereoselectivities of the reactions using resulting alternative *O*-acetyl (Ac)-*N*-Boc iminium ion **13** and *O*-benzoyl (Bz)-*N*-methoxycarbonyl (Moc) iminium ion **20**, respectively, as shown in Scheme 3. Thus, after removal of TBS protecting group of **3** with *n*-Bu₄NF, sequential acetylation of the resulting alcohol **9** afforded *O*-Ac protected lactam **10**. By employing the reaction sequence similar to that described for the preparation of **7** and **8** from **3**, **10** was converted to 2-cyanopyrrolidines (**14a/b**) in 70% yield (3 steps), as an inseparable diastereomeric mixture (**14a**:**14b**=58:42 by 400MHz ¹H-NMR analysis) via 2-hydroxypyrrolidine **11** and 2-methoxypyrrolidine **12**. The diastereoselectivity was not improved. As a further exchange of both *N*- and *O*-protecting groups of **13**, *O*-Bz-*N*-Moc lactam **17** was prepared from the alcohol **9** via 3-step sequence as follows: 1) benzylation of **9**, 2) deprotection of *N*-Boc group of **15**, and 3) *N*-protection of **16** with methyl chlorocarbonate (MocCl) in the presence of lithium bis(trimethylsilyl)amide (LiN(TMS)₂) as base at -15°C.⁹



Reagents and Conditions : a) *n*-Bu₄NF, THF, r.t., 92% b) Ac₂O, pyridine, 0°C–r.t., 95% c) LiEt₃BH, THF, -78°C d) PPTS, MeOH, r.t., 82% for **12** (2 steps), 80% for **19** (2 steps) e) TMSCN, BF₃ · Et₂O, CH₂Cl₂, -78°C, 85% (**14a**:**14b**=58:42), 82% (**21**:**22**=72:28) f) BzCl, pyridine, 0°C–r.t., 82% g) TFA, CH₂Cl₂, r.t., 90% h) MocCl, LiN(TMS)₂, THF, -15°C, 86% i) 6M HCl, 115°C; Dowex 50w x 8, 75–78%


Scheme 3

The same reaction sequence for the preparation of **7** and **8** from **3** was applied to **17**, giving rise to the desired 2,3-*trans*-2-cyanopyrrolidine **21** and its *cis*-isomer **22** in a ratio of 72: 28 in 82% combined yield, via 2-hydroxypyrrolidine **18** and 2-methoxypyrrolidine **19**.

The stereochemistries of the stereogenic center at C₂ in both **21** and **22** were proven by NOE measurements in their 400 MHz ¹H-NMR spectra. Thus, for the compound **21**, irradiation of the C₅-H resulted in enhancement of the signal due to the C₂-H and irradiation of the C₃-H gave no enhancement of the signal due to the C₂-H. For the compound **22**, irradiation of the C₃-H resulted in enhancement of the signal due to the C₂-H and irradiation of the C₅-H gave no enhancement of the signal due to the C₂-H. Accordingly, C₂-H and C₃-H in **21** and **22** were assigned to have *trans*- and *cis*-configurations, respectively. Thus, absolute configurations of these compounds **21** and **22** were unambiguously determined as (2*R*,3*R*,5*R*)-**21** and (2*S*,3*R*,5*R*)-**22**, respectively.

The stereoselectivity observed for the nucleophilic addition of a cyanide anion to iminium ions **6** and **20** can be explained by the preferred transition state conformations of **6** and **20** as shown in Figure 2. Thus, the conformers **6B** and **20B** is expected to be more favored than the other conformers **6A** and **20A** which have A^{1,2}-strain between the *N*-protecting groups (Boc and Moc) and the methyl groups. The improved *trans*-selectivity in the case of the *O*-Bz-*N*-Moc iminium ion intermediate **20** can be explained by the known ability of the carbonyl oxygen of the benzoyloxy group to bridge to adjacent cationic center (transition state **20B**),^{6a,10} and hence a cyanide anion may approach the cation center preferentially from the opposite side to the benzoyl group. Also, good *trans*-selectivity in the case of *O*-Bz iminium ion intermediate **20** than the case of the *O*-Ac intermediate **13** can be explainable by both of the stability of the benzylic cation of the transition state **20C** and the steric bulkiness of the phenyl ring. Whereas a less satisfactory diastereoselectivity in the case of the *O*-TBS-

Figure 2




N-Boc iminium ion intermediate **6** can be explained by assuming that the attack of a cyanide anion occur preferentially from the same side of *O*-TBS group of **6** under an influence of stereoelectronic effect^{5d,11} (transition state **6B**), giving rise to undesirable **8** as a major product. Finally, the acidic hydrolysis of both **21** and **22** with 6M HCl at 110°C for 24h afforded the target free amino acids (2*R*, 3*R*, 5*R*)-**1**, [α]²⁵_D +18.6° (c 1.02, H₂O); lit.³ [α]_D +18° (c 0.32, H₂O), in 75% yield, and its isomer (2*S*,3*R*,5*R*)-**1**, [α]²⁰_D -85.1° (c 0.70, H₂O), in 78% yield, respectively, after ion-exchange chromatography on Dowex 50W x 8 (Scheme 3).

The stereochemical assignment of (2*R*, 3*R*, 5*R*)-**1** and (2*S*,3*R*,5*R*)-**1** were made on the basis of NOE experiments. Thus, for the compound (2*R*, 3*R*, 5*R*)-**1**, irradiation of the C₄-H α (δ 2.18) resulted in enhancements both of the signals due to the C₂- and C₅-H (δ 3.98-4.10) and irradiation of the C₃-H (δ 4.64-4.77) gave no enhancement of the signal due to the C₂-H. For the compound (2*S*,3*R*,5*R*)-**1**, irradiation of the C₃-H (δ 4.70) resulted in enhancements both of the signals due to the C₂-H (δ 4.24) and C₄-H (δ 1.91). Accordingly, C₂-H and C₄-H in (2*R*,3*R*,5*R*)-**1** and (2*S*,3*R*,5*R*)-**1** were assigned to have *trans*- and *cis*-configurations, respectively. No epimerization of the C₂ stereogenic centers in both (2*R*,3*R*,5*R*)-**1** and (2*S*,3*R*,5*R*)-**1** had occurred during the hydrolysis described above. The structure was confirmed by the reported (2*R*,3*R*,5*R*)-**1**, whose ¹H- and ¹³C- NMR spectra data were in good agreement with the literature data³ of its enantiomer (2*S*,3*S*,5*S*)-**1**.

2. Synthesis of (2*S*,3*S*,5*S*)-**1**

For the synthesis of (2*S*,3*S*,5*S*)-**1**, the intermediate (3*R*,5*S*)-*N*-Boc-3-hydroxylactam **25** derived from (3*R*,5*S*)-**23**,¹² was submitted to the Mitsunobu inversion¹³ followed by exchange *N*-Boc protecting group with *N*-Moc group to give *ent*-**17**. Conversion of *ent*-**17** to *ent*-**21** was achieved by the procedure similar to that described above, and the *ent*-**21** was hydrolyzed to afford the target free amino acid (2*S*,3*S*,5*S*)-**1**,



Reagents and Conditions : a) RuO₂ · xH₂O, 10% aq. NaIO₄, AcOEt, 92% b) *n*-Bu₄NF, THF, r.t., 88% c) PPh₃, DEAD, PhCO₂H, 0°C~r.t., 85% d) TFA, CH₂Cl₂, r.t., 90% e) MocCl, LIN(TMS)₂, THF, -15°C~r.t., 82% f) LiEt₃BH, THF, -78°C g) PPTS, MeOH, r.t., 85%, 2 steps h) TMSCN, BF₃ · Et₂O, CH₂Cl₂, -78°C, 84% (*ent*-**21**: *ent*-**22**=80:20) i) 6M HCl, 115°C; Dowex 50w x 8, 70%

Scheme 4

$[\alpha]^{24}_{\text{D}} -17.6^\circ$ (c 0.80, H₂O); lit.³ $[\alpha]_{\text{D}} -17^\circ$ (c 0.50, H₂O), in 70% yield, whose spectra data were in good agreement with the literature data³ of (2*S*,3*S*,5*S*)-**1**.

In summary, a novel diastereoselective syntheses of (2*R*,3*R*,5*R*)-**1** and its enantiomer (2*S*,3*S*,5*S*)-**1** were accomplished by employing the *trans*-selective nucleophilic addition of cyanide anion to the 3-benzoyloxy-*N*-acyliminium ions as the key step, starting from *trans*-4-hydroxy-*L*-proline.

Experimental

General. Melting points were measured on a Yanaco MP-S3 micro melting point apparatus and uncorrected. Optical rotations were measured with a JASCO DIP-370 automatic digital polarimeter. Infrared (IR) spectra were recorded with a Hitachi 270-30 spectrometer. ¹H- and ¹³C-NMR spectra were measured with a JNM- GSX400 (400 MHz) or a JNM-EX90 (90 MHz) spectrometer. The chemical shifts were expressed in ppm (δ) downfield from tetramethylsilane as internal standard in CDCl₃ solutions, or from 3-(trimethylsilyl)-1-propane-sulfonic acid sodium salt as internal standard in D₂O solutions. The following abbreviation are used: singlet (s), doublet (d), triplet (t), multiplet (m), and broad (br). Electron impact mass spectra (EIMS) and high resolution mass spectra (HRMS) were obtained with JMS DX-300 spectrometer. Routine monitoring of reactions was carried out using Merck TLC aluminium sheet silica gel 60 F254. Column chromatography was performed on Merck silica gel, 70-230 mesh. Usual workup means that organic layer was dried over magnesium sulfate, and evaporated *in vacuo*. The *trans*-4-hydroxy-*L*-proline as a chiral starting material was purchased from Sigma Chemical Co.

Material. (3*R*,5*R*)-**1**-(*tert*-Butoxycarbonyl)-4-(*tert*-butyldimethylsilyl)oxy-2-methylpyrrolidine (**2**) and Its (3*R*,5*S*)-Isomer (**23**) were prepared from *trans*-4-hydroxy-*L*-proline according to the reported method.⁸ *cis*-4-Hydroxy-*D*-proline was prepared from *trans*-4-hydroxy-*L*-proline according to the reported method.¹²

(3*R*,5*R*)-**1**-(*tert*-Butoxycarbonyl)-3-(*tert*-butyldimethylsilyl)oxy-5-methyl-2-pyrrolidinone (**3**) and Its (3*R*,5*S*)-Isomer (**24**)

a) Preparation of **3** from **2**: A solution of **2** (10.8 g, 26 mmol) in ethyl acetate (80 ml) was added to a mixture of RuO₂·xH₂O (0.4 g) and 10% aqueous NaIO₄ (120 ml). The solution was stirred vigorously for 3 h at room temperature. The layer was separated and the aqueous layer was extracted with ethyl acetate (80 ml). The extract was treated with 2-propanol (0.2 ml). Black-colored RuO₂ which precipitated from the solution was filtered off and the filtrate was washed with brine, and usual workup gave a residue which was purified by column chromatography (hexane: ethyl acetate=6:1) to give **3** (7.6 g, 88%) as a colorless oil. $[\alpha]^{23}_{\text{D}} +13.4^\circ$ (c 1.04, MeOH). IR (neat): 1798, 1768, 1726 cm⁻¹. ¹H-NMR (CDCl₃): δ 0.13, 0.18 (6H, each s, Si(CH₃)₂), 0.91 (9H, s, SiC(CH₃)₃), 1.31 (3H, d, J=6.23 Hz, CH₃), 1.53 (9H, s, C(CH₃)₃), 2.03-2.14 (2H, m, C₄-H₂), 4.15-4.24 (1H, m, C₅-H), 4.45 (1H, t, J=8.80 Hz, C₃-H₂). ¹³C-NMR (CDCl₃): δ -5.28, -4.44, 18.29, 20.58, 25.75, 28.04, 36.04, 49.67, 70.23, 82.95, 150.05, 172.81. HRMS: calcd for C₁₆H₃₂NO₄Si (M+H)⁺: 330.2100. Found: 330.2088.

b) Preparation of **24** from **23**: Treatment of **23** (8.6 g, 27 mmol) in the same manner as described for the preparation of **3** from **2** gave **24** (8.3 g, 92%) as a colorless oil. $[\alpha]^{25}_D +43.3^\circ$ (c 1.10, MeOH). IR (neat): 1794, 1764, 1726 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 0.13, 0.15 (6H, each s, $\text{Si}(\text{CH}_3)_2$), 0.90 (9H, s, $\text{SiC}(\text{CH}_3)_3$), 1.42 (3H, d, $J=6.23$ Hz, CH_3), 1.53 (9H, s, $\text{OC}(\text{CH}_3)_3$), 1.50–1.62 (1H, m, $\text{C}_4\text{-H}\alpha$), 2.37 (1H, ddd, $J=13.19, 7.33, 1.02$ Hz, $\text{C}_4\text{-H}\beta$), 3.98–4.80 (1H, m, $\text{C}_5\text{-H}$), 4.22 (1H, dd, $J=7.69, 6.23$ Hz, $\text{C}_3\text{-H}$). $^{13}\text{C-NMR}$ (CDCl_3): δ –5.25, –4.53, 18.19, 21.75, 25.72, 28.07, 35.79, 51.34, 71.27, 82.92, 150.24, 172.87. HRMS: calcd for $\text{C}_{16}\text{H}_{32}\text{NO}_4\text{Si}$ ($\text{M}+\text{H}^+$): 330.2100. Found: 330.2082.

(3*R*,5*R*)-1-(*tert*-Butoxycarbonyl)-3-(*tert*-butyldimethylsilyl)oxy-5-methyl-2-methoxy-pyrrolidine (5**)**

Lithium triethylborohydride in THF (1.0 M solution, 14.4 ml, 14.4 mmol) was added to a solution of **3** (4.0 g, 12 mmol) in THF (50 ml) at -78°C under nitrogen atmosphere. After 30 min, the reaction was quenched with saturated aqueous NaHCO_3 and the mixture was allowed to warm up to room temperature. The mixture was extracted with ethyl acetate (80 ml). Usual workup afforded (3*R*,5*R*)-1-(*tert*-Butoxycarbonyl)-3-(*tert*-butyldimethylsilyl)oxy-2-hydroxy-5-methylpyrrolidine (**4**) (3.85 g), which was dissolved in methanol (50 ml). The methanolic solution of **4** was treated with a catalytic amount of pyridinium *p*-toluenesulfonate (0.25 g, 1.0 mmol) for 12h at room temperature. The mixture was diluted with ethyl acetate. The organic layer was washed successively with 10% aqueous citric acid, saturated aqueous NaHCO_3 , and brine. Usual workup followed by column chromatography (hexane: ethyl ether=6:1) gave **5** (3.1 g, 75%, 2 steps) as a mixture of two diastereomers. This material was directly used for the next step without separation. IR (neat): 1715 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 0.05, 0.06 (6H, m, $\text{Si}(\text{CH}_3)_2$), 0.85 (9H, s, $\text{SiC}(\text{CH}_3)_3$), 1.27 (3H, br d, $J=6.25$ Hz, CH_3), 1.48 (9H, br s, $\text{OC}(\text{CH}_3)_3$), 1.72–2.02 (2H, m, $\text{C}_4\text{-H}_2$), 3.31, 3.34 (3H, each s, OCH_3), 3.88–4.02 (1H, m, $\text{C}_5\text{-H}$), 4.82–4.98 (1H, m, $\text{C}_3\text{-H}$). $^{13}\text{C-NMR}$ (CDCl_3): δ –4.88, –4.82, –4.67, 17.89, 21.65, 21.73, 22.18, 22.27, 25.48, 25.63, 28.20, 28.40, 40.01, 40.12, 40.55, 40.68, 52.63, 54.57, 54.70, 54.78, 54.85, 73.90, 74.49, 79.54, 79.57, 79.63, 95.09, 155.24, 155.26. HRMS calcd for $\text{C}_{17}\text{H}_{36}\text{NO}_4\text{Si}$ ($\text{M}+\text{H}^+$): 346.2414. Found: 346.2408.

(2*R*,3*R*,5*R*)-1-(*tert*-Butoxycarbonyl)-3-(*tert*-butyldimethylsilyl)oxy-2-cyano-5-methyl-pyrrolidine (7**) and Its (2*S*,3*R*,5*R*)-Isomer (**8**)**

Trimethylsilyl cyanide (1.50 ml, 11mmol) and boron trifluoride etherate (1.40 ml, 11 mmol) were added successively to a stirred solution of **5** (2.6 g, 7.5 mmol) in dry dichloromethane (20 ml) at -78°C under nitrogen. After 1.5 h, the reaction was quenched with saturated Na_2CO_3 (8 ml) at -78°C , and the mixture was allowed to warm up to room temperature. The mixture was extracted with dichloromethane (60 ml). Usual workup followed by column chromatography (hexane: ethyl acetate=5:1) gave **7** (0.65 g, 25%) as a more polar product and **8** (1.5 g, 59%) as a less polar product.

7: colorless oil. $[\alpha]^{25}_D +6.6^\circ$ (c 0.94, MeOH). IR (neat): 2220, 1698 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 0.06–0.10 (6H, m, $\text{Si}(\text{CH}_3)_2$), 0.93 (9H, s, $\text{SiC}(\text{CH}_3)_3$), 1.21 (3H, d, $J=6.23$ Hz, CH_3), 1.51 (9H, s, $\text{OC}(\text{CH}_3)_3$), 1.80–

1.92 (1H, m, C₄-H_β), 2.16–2.32 (1H, m, C₄-H_α), 3.92–4.10 (2H, m, C₂-, C₅-H), 4.47–4.56 (1H, m, C₃-H). ¹³C-NMR (CDCl₃): δ -4.95, -4.82 (Si(CH₃)₂), 17.98 (SiC(CH₃)₃), 21.22, 21.86 (CH₃), 25.54 (SiC(CH₃)₃), 28.20 (OC(CH₃)₃), 39.42 (C₄), 53.71 (C₅), 54.13 (C₄), 69.69 (C₃), 81.50 (OC(CH₃)₃), 116.19 (CN), 156.62 (C=O). HRMS calcd for C₁₇H₃₂N₂O₃Si (M⁺): 340.2182. Found: 340.2172.

8: colorless prisms. mp 77–78°C (ethyl acetate-isopropyl ether). [α]_D²⁵ -34.1° (c 1.15, MeOH). IR (KBr): 2220, 1712 cm⁻¹. ¹H-NMR (CDCl₃): δ 0.06–0.10 (6H, m, Si(CH₃)₂), 0.93 (9H, s, SiC(CH₃)₃), 1.20 (3H, d, J=6.23 Hz, CH₃), 1.51 (9H, s, OC(CH₃)₃), 1.80–1.90 (1H, m, C₄-H_β), 2.17–2.30 (1H, m, C₄-H_α), 3.88–4.10 (2H, m, C₂-, C₅-H), 4.45–4.56 (1H, m, C₃-H). ¹³C-NMR (CDCl₃): δ -4.93, -4.80 (Si(CH₃)₂), 17.99 (SiC(CH₃)₃), 21.19, 21.25 (CH₃), 25.63 (SiC(CH₃)₃), 28.36 (OC(CH₃)₃), 39.85 (C₄), 51.48 (C₅), 54.13 (C₂), 69.48 (C₃), 81.30 (OC(CH₃)₃), 116.13 (CN), 155.98 (C=O). Anal. Calcd for C₁₇H₃₂N₂O₃Si: C, 59.96; H, 9.47; N, 8.22. Found: C, 59.86; H, 9.38; N, 8.04.

(3*R*,5*R*)-1-(*tert*-Butoxycarbonyl)-3-hydroxy-5-methyl-2-pyrrolidinone (9) and Its (3*R*,5*S*)-Isomer (25)

a) Preparation of **9** from **3**: Tetra-*n*-butylammonium fluoride (TBAF) in THF (1.0 M solution, 20 ml, 20.0 mmol) was added dropwise to a stirred solution of **3** (5.5 g, 16.7 mmol) in THF (60 ml) at room temperature for 3 h. The reaction mixture was concentrated, and the residue was purified by column chromatography (ethyl acetate: benzene=2:1) to give **9** (3.3 g, 92%) as a colorless solid. Recrystallization from ethyl acetate: isopropyl ether gave an analytical sample of **9** as colorless prisms, mp 112–113°C. [α]_D²⁴ +4.6° (c 1.19, MeOH). IR (KBr): 3620–3200, 1786, 1748 cm⁻¹. ¹H-NMR (CDCl₃): δ 1.33 (3H, d, J=6.23 Hz, CH₃), 1.54 (9H, s, OC(CH₃)₃), 2.05–2.24 (2H, m, C₄-H₂), 3.30–3.54 (1H, br s, OH), 4.20–4.29 (1H, m, C₅-H), 4.50 (1H, dd, J=11.36, 8.43 Hz, C₃-H). ¹³C-NMR (CDCl₃): δ 20.43, 28.01, 34.58, 50.53, 69.18, 83.46, 149.54, 174.94. EIMS m/z: 215 (M⁺). Anal. Calcd for C₁₀H₁₇NO₄: C, 55.80; H, 7.96; N, 6.51. Found: C, 55.68; H, 7.84; N, 6.50.

b) Preparation of **25** from **24**: Treatment of **24** (6.9 g, 20.9 mmol) in the same manner as described for the preparation of **9** from **3** gave **25** (3.9 g, 88%) as a colorless solid. Recrystallization from ethyl acetate: isopropyl ether gave an analytical sample of **25** as colorless prisms, mp 97–98°C. [α]_D²⁵ +75.1° (c 1.22, MeOH). IR (KBr): 3420–3200, 1788, 1695 cm⁻¹. ¹H-NMR (CDCl₃): δ 1.43 (3H, d, J=6.23 Hz, CH₃), 1.53 (9H, s, OC(CH₃)₃), 1.56–1.66 (1H, m, C₄-H_α), 2.52–2.62 (1H, m, C₄-H_β), 3.62 (1H, br s, OH), 3.96–4.05 (1H, m, C₅-H), 4.33 (1H, t, J=8.43 Hz, C₃-H). ¹³C-NMR (CDCl₃): δ 21.79, 28.02, 34.52, 51.07, 69.93, 83.37, 149.85, 175.10. Anal. Calcd for C₁₀H₁₇NO₄: C, 55.80; H, 7.96; N, 6.51. Found: C, 55.72; H, 7.78; N, 6.46.

(3*R*,5*R*)-3-Acetoxy-1-(*tert*-butoxycarbonyl)-5-methyl-2-pyrrolidinone (10)

Alcohol **9** (2.5 g, 12 mmol) was dissolved in a mixture of acetic anhydride (30 ml) and dry pyridine (30 ml) at 0°C, and the solution was stirred at room temperature for 20 h. The solvents were removed *in vacuo* and the residue was dissolved in ethyl acetate (50 ml). The solution was washed successively with 10% aqueous citric acid, saturated aqueous NaHCO₃, and brine. Usual workup followed by column chromatography (hexane: ethyl

acetate=2:1) gave **10** (2.8 g, 95%) as a colorless oil. $[\alpha]^{24}_D +25.7^\circ$ (c 1.16, MeOH). IR (neat): 1798, 1754, 1724 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.37 (3H, d, $J=6.23$ Hz, CH_3), 1.54 (9H, s, $\text{OC}(\text{CH}_3)_3$), 2.15 (3H, s, COCH_3), 2.17 (1H, ddd, $J=12.45, 10.99, 8.79$ Hz, $\text{C}_4\text{-H}_\beta$), 2.26 (1H, ddd, $J=12.45, 8.43, 2.20$, $\text{C}_4\text{-H}_\alpha$), 4.26–4.34 (1H, m, $\text{C}_5\text{-H}$), 5.54 (1H, dd, $J=10.99, 8.43$ Hz, $\text{C}_3\text{-H}$). $^{13}\text{C-NMR}$ (CDCl_3): δ 20.55, 27.99, 32.53, 50.24, 69.97, 83.53, 149.60, 169.17, 170.01. HRMS calcd for $\text{C}_{12}\text{H}_{19}\text{NO}_5$ (M^+): 257.1263. Found: 257.1248.

(3*R*,5*R*)-3-Acetoxy-1-(*tert*-butoxycarbonyl)-2-methoxy-5-methylpyrrolidine (12**)**

Treatment of **10** (2.4 g, 9.3 mmol) in a similar manner to that described for the preparation of **5** from **3** gave **12** (2.1 g, 82%, 2 steps) as a mixture of two diastereomers *via* (3*R*, 5*R*)-3-acetoxy-1-(*tert*-butoxycarbonyl)-2-hydroxy-5-methylpyrrolidine (**11**) after purification by column chromatography (hexane: ethyl acetate=3:1). This material was directly used for the next reaction without further separation.

12: colorless oil. IR (neat): 1745, 1690 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.28–1.33 (3H, m, CH_3), 1.50 (9H, s, $\text{OC}(\text{CH}_3)_3$), 2.01 (3H, s, COCH_3), 1.90–2.20 (2H, m, $\text{C}_4\text{-H}_2$), 3.37 (3H, br s, OCH_3), 3.88–4.10 (1H, m, $\text{C}_5\text{-H}$), 4.93–5.10 (1H, m, $\text{C}_3\text{-H}$). HRMS calcd for $\text{C}_{13}\text{H}_{24}\text{NO}_5$ ($\text{M}+\text{H}^+$): 274.1655. Found: 274.1642.

(2*R*,3*R*,5*R*)-3-Acetoxy-1-(*tert*-butoxycarbonyl)-2-cyano-5-methylpyrrolidine and Its (2*S*,3*R*,5*R*)-Isomer (14a/b**)**

Treatment of **12** (0.8 g, 2.9 mmol) in a similar manner to that described for the preparation of **7** and **8** from **5** gave **14a/b** (0.67 g, 85%, *a:b*=58:42) as a mixture of two diastereomers after purification by column chromatography (hexane: ethyl acetate=3:1). colorless oil. $[\alpha]^{21}_D +8.0^\circ$ (c 1.60, MeOH). IR (neat): 2240, 1754, 1716 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.24, 1.39 (total 3H, each d, $J=6.23$ Hz, CH_3), 1.51 (9H, s, $\text{OC}(\text{CH}_3)_3$), 2.08, 2.17 (total 3H, each s, COCH_3), 2.00–2.45 (2H, m, $\text{C}_4\text{-H}_2$), 3.97–4.15 (1H, m, $\text{C}_5\text{-H}$), 4.50–4.75 (1H, m, $\text{C}_2\text{-H}$), 5.20–5.35 (1H, m, $\text{C}_3\text{-H}$). HRMS calcd for $\text{C}_{13}\text{H}_{21}\text{N}_2\text{O}_4$ ($\text{M}+\text{H}^+$): 269.1501. Found: 269.1492.

(3*R*,5*R*)-3-Benzoyloxy-1-(*tert*-butoxycarbonyl)-5-methyl-2-pyrrolidinone (15**) and Its Enantiomer (*ent*-**15**)**

a) Preparation of **15** from **9**: To a stirred solution of alcohol **9** (3.1 g, 14.4 mmol) in dry pyridine (50 ml) was added benzoyl chloride (2.4 g, 17.3 mmol) at 0°C and the mixture was stirred at room temperature for 20 h. The solvent was removed *in vacuo* and the residue was dissolved in ethyl acetate (50 ml). The solution was washed successively with 10% aqueous citric acid, saturated aqueous NaHCO_3 , and brine. Usual workup followed by column chromatography (hexane: ethyl acetate=4:1) gave **15** (3.7 g, 82%) as a colorless solid. Recrystallization from petroleum ether gave an analytical sample of **15** as colorless needles, mp $86\text{--}87^\circ\text{C}$. $[\alpha]^{20}_D -6.9^\circ$ (c 1.56, MeOH). IR (KBr): 1794, 1768, 1726, 1598 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.42 (3H, d, $J=6.60$ Hz, CH_3), 1.56 (9H, s, $\text{OC}(\text{CH}_3)_3$), 2.28 (1H, ddd, $J=12.45, 10.99, 8.79$ Hz, $\text{C}_4\text{-H}_\beta$), 2.39 (1H, ddd, $J=12.45, 8.43, 1.10$

Hz, C₄-H_α), 4.30–4.42 (1H, m, C₅-H), 5.76 (1H, dd, J=10.99, 8.43 Hz, C₃-H), 7.40–8.12 (5H, m, aromatic-H). ¹³C-NMR (CDCl₃): δ 20.65, 28.02, 32.80, 50.30, 70.47, 83.60, 128.41, 129.14, 130.01, 133.49, 149.70, 165.64, 169.09. EIMS m/z: 319 (M⁺). Anal. Calcd for C₁₇H₂₁NO₅: C, 63.93; H, 6.63; N, 4.39. Found: C, 63.77; H, 6.60; N, 4.40.

b) Preparation of *ent*-15 from 25: To a stirred solution of alcohol 24 (3.5 g, 16.2 mmol) in THF (80 ml) was added benzoic acid (3.9 g, 32.5 mmol) followed by PPh₃ (8.5 g, 32.5 mmol). The solution was then cooled to 0°C, and a solution of diethyl azodicarboxylate (DEAD, 5.6 g, 32.5 mmol) in THF (20 ml) was added dropwise. The reaction mixture was stirred for 1 h at 0°C, and 15 h at room temperature. The reaction mixture was concentrated *in vacuo* to give a thick yellow oil residue. The residue was dissolved in dichloromethane (100 ml) and the solution was washed with saturated aqueous NaHCO₃ and brine. Usual workup followed by column chromatography (hexane: ethyl acetate=4:1) gave *ent*-15 (4.4 g, 85%) as a colorless oil. [α]_D²⁵ +6.7° (c 1.60, MeOH). The IR, ¹H-NMR, ¹³C-NMR, and mass spectra of this material were identical with those recorded for 15.

(3*R*,5*R*)-3-Benzoyloxy-5-methyl-2-pyrrolidinone (16) and Its Enantiomer (*ent*-16)

a) Preparation of 16 from 15: Trifluoroacetic acid (5 ml) was added to a stirred solution of 15 (2.5g, 7.8 mmol) in dichloromethane (20 ml) at 0°C. The reaction mixture was stirred for 2 h at room temperature and then the solvent was evaporated *in vacuo*. The residue was dissolved in ethyl acetate (50 ml) and the solution was washed with saturated aqueous NaHCO₃ and brine. Usual workup gave 16 (1.54 g, 90%) as a colorless solid. Recrystallization from ethyl acetate: isopropyl ether gave an analytical sample of 16 as colorless needles, mp 154–155°C. [α]_D²⁰ +42.5° (c 1.27, MeOH). IR (KBr): 3240, 1730, 1714, 1676, 1600 cm⁻¹. ¹H-NMR (CDCl₃): δ 1.30 (3H, d, J=6.23 Hz, CH₃), 2.30 (1H, ddd, J=13.92, 8.43, 8.06 Hz, C₄-H_β), 2.35 (1H, ddd, J=13.92, 6.59, 1.47 Hz, C₄-H_α), 3.89–3.98 (1H, m, C₅-H), 5.59 (1H, dd, J=8.06, 6.59 Hz, C₃-H), 7.38 (1H, br s, NH), 7.43–8.13 (5H, m, aromatic-H). ¹³C-NMR (CDCl₃): δ 22.70, 35.95, 47.49, 71.12, 128.38, 129.44, 129.94, 133.34, 165.93, 173.20. EIMS m/z: 220 (M+H)⁺. Anal. Calcd for C₁₂H₁₃NO₃: C, 65.74; H, 5.98; N, 6.39. Found: C, 65.68; H, 6.00; N, 6.26.

b) Preparation of *ent*-16 from *ent*-15: Treatment of *ent*-15 (4.2 g, 13.1 mmol) in the same manner as described for the preparation of 16 from 15 gave *ent*-16 (2.6 g, 90%) as colorless needles. mp 154–155°C (ethyl acetate:isopropyl ether). [α]_D²² -41.8° (c 1.20, MeOH). The IR, ¹H-NMR, ¹³C-NMR, and mass spectra of this material were identical with those recorded for 16.

(3*R*,5*R*)-3-Benzoyloxy-1-methoxycarbonyl-5-methyl-2-pyrrolidinone (17) and Its Enantiomer (*ent*-17)

a) Preparation of 17 from 16: Lithium bis(trimethylsilyl)amide (LiN(TMS)₂) in THF (1.0 M solution, 8.2 ml, 8.2 mmol) was added to a solution of 16 (1.5 g, 6.8 mmol) in dry THF (30 ml) under nitrogen at -15°C, and the reaction mixture was stirred for 30 min. Then methyl chlorocarbonate (0.78 g, 8.2 mmol) was added to the reaction mixture. After stirring for 1 h at -15°C and the reaction mixture was allowed to warm up to room temperature. The reaction was quenched with saturated NH₄Cl solution (10 ml) and the mixture was extracted

with ethyl acetate (50 ml). Usual workup followed by column chromatography (chloroform: methanol=30:1) gave **17** (1.6 g, 86%) as a colorless solid. Recrystallization from ethyl acetate: isopropyl ether gave an analytical sample of **17** as colorless needles, mp 129–130°C. $[\alpha]^{22}_{\text{D}} -20.4^\circ$ (c 0.82, MeOH). IR (KBr): 1768, 1720, 1604 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.44 (3H, d, $J=6.60$ Hz, CH_3), 2.31 (1H, ddd, $J=12.46, 10.99, 10.62$ Hz, $\text{C}_4\text{-H}_\beta$), 2.42 (1H, ddd, $J=12.46, 8.43, 1.73$ Hz, $\text{C}_4\text{-H}_\alpha$), 3.91 (3H, s, OCH_3), 4.38–4.47 (1H, m, $\text{C}_5\text{-H}$), 5.76 (1H, dd, $J=10.62, 8.43$ Hz, $\text{C}_3\text{-H}$), 7.40–8.10 (5H, m, aromatic-H). $^{13}\text{C-NMR}$ (CDCl_3): δ 20.58, 32.91, 50.59, 53.78, 70.41, 128.47, 129.05, 130.00, 133.58, 151.92, 165.57, 168.95. EIMS m/z : 277 (M^+). Anal. Calcd for $\text{C}_{14}\text{H}_{15}\text{NO}_5$: C, 60.64; H, 5.45; N, 5.05. Found: C, 60.44; H, 5.32; N, 4.85.

b) Preparation of *ent*-**17** from *ent*-**16**: Treatment of *ent*-**16** (2.2 g, 10.0 mmol) in the same manner as described for the preparation of **16** from **15** gave *ent*-**17** (2.3 g, 82%) as colorless needles, mp 128–129°C (ethyl acetate: isopropyl ether). $[\alpha]^{25}_{\text{D}} +20.8^\circ$ (c 1.12, MeOH). The IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and mass spectra of this material were identical with those recorded for **17**.

(3*R*,5*R*)-3-Benzoyloxy-2-methoxy-1-methoxycarbonyl-5-methylpyrrolidine (**19**) and Its Enantiomer (*ent*-**19**)

a) Preparation of **19**: Treatment of **17** (1.5 g, 5.4 mmol) in a similar manner to that described for the preparation of **5** from **3** gave **19** (1.27 g, 80%) as a mixture of diastereomers. This material was directly used for the next reaction without separation. In a small scale experiment, this diastereomers was further separated by column chromatography (benzene: ethyl acetate=3:1) to give pure samples of more polar **19** and less polar **19** in a ratio of 75: 25.

More polar 19: colorless needles (ethyl acetate: isopropyl ether), mp 128–129°C. $[\alpha]^{24}_{\text{D}} -12.5^\circ$ (c 1.02, MeOH). IR (KBr): 1768, 1720, 1608 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.44 (3H, d, $J=6.23$ Hz, CH_3), 2.33 (1H, ddd, $J=12.43, 10.62, 8.43$ Hz, $\text{C}_4\text{-H}$), 2.43 (1H, ddd, $J=12.43, 8.43, 1.10$ Hz, $\text{C}_4\text{-H}$), 3.91 (3H, s, OCH_3), 3.87–3.98 (1H, m, $\text{C}_5\text{-H}$), 4.36–4.45 (1H, m, $\text{C}_2\text{-H}$), 5.77 (1H, dd, $J=10.62, 8.43$ Hz, $\text{C}_3\text{-H}$), 7.42–8.08 (5H, m, aromatic-H). EIMS m/z : 262 (M-OCH_3) $^+$. Anal. Calcd for $\text{C}_{15}\text{H}_{19}\text{NO}_5$: C, 61.42; H, 6.53; N, 4.78. Found: C, 61.33; H, 6.42; N, 4.58.

Less polar 19: colorless oil. $[\alpha]^{24}_{\text{D}} +7.6^\circ$ (c 0.88, MeOH). IR (neat): 1765, 1718, 1606 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.24 (3H, d, $J=6.59$ Hz, CH_3), 2.06–2.14 (1H, m, $\text{C}_4\text{-H}$), 2.21–2.30 (1H, m, $\text{C}_4\text{-H}$), 3.76 (3H, s, OCH_3), 3.98–4.08 (1H, m, $\text{C}_5\text{-H}$), 4.60–4.68 (1H, m, $\text{C}_2\text{-H}$), 5.37–5.42 (1H, m, $\text{C}_3\text{-H}$), 7.42–8.16 (5H, m, aromatic-H). HRMS calcd for $\text{C}_{14}\text{H}_{16}\text{NO}_4$ (M-OCH_3) $^+$: 262.1079. Found: 269.1060.

b) Preparation of *ent*-**19** from *ent*-**17**: The same treatment of *ent*-**17** (2.1 g, 7.5 mmol) as described for the preparation of **19** from **17** gave *ent*-**19** (1.9 g, 85%, 2 steps) as a mixture of two diastereomers via *ent*-**18**. This material was directly used for the next reaction without separation. In a small scale experiment, this diastereomers was further separated by column chromatography (benzene: ethyl acetate=3:1) to give pure samples of more polar *ent*-**19** and less polar *ent*-**19** in a ratio of 74:26.

More polar ent-19: colorless needles, mp 128–129°C (ethyl acetate: isopropyl ether). $[\alpha]^{25}_{\text{D}} +12.3^\circ$ (c 1.22, MeOH). The IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and mass spectra of this material were identical with those recorded for more polar **19**.

Less polar *ent*-19: colorless oil. $[\alpha]^{25}_D -7.4^\circ$ (c 0.76, MeOH). The IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and mass spectra of this material were identical with those recorded for less polar **19**.

(2*R*,3*R*,5*R*)-3-Benzoyloxy-2-cyano-1-methoxycarbonyl-5-methylpyrrolidine (21), Its (2*S*,3*R*,5*R*)-Isomer (22), Its (2*S*,3*S*,5*S*)-Isomer (*ent*-21) and Its (2*R*,3*S*,5*S*)-Isomer (*ent*-22)

a) Preparation of **21** and **22**: Treatment of **19** (1.2 g, 4.1 mmol) in a similar manner to that described for the preparation of **7** and **8** from **5** gave **21** (0.70 g, 59%) as a more polar product and **22** (0.27 g, 23%) as a less polar product after separation by column chromatography (hexane: ethyl acetate=5:1).

21: colorless needles (ethyl acetate:petroleum ether), mp 86–87°C. $[\alpha]^{21}_D -37.5^\circ$ (c 1.32, MeOH). IR (KBr): 2220, 1725, 1603 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.47 (3H, s, CH_3), 2.24 (1H, br s, $\text{C}_4\text{-H}_\beta$), 2.48–2.58 (1H, m, $\text{C}_4\text{-H}_\alpha$), 3.78 (3H, s, OCH_3), 4.22 (1H, br s, $\text{C}_5\text{-H}$), 4.76 (1H, br s, $\text{C}_2\text{-H}$), 5.60 (1H, br s, $\text{C}_3\text{-H}$), 7.38–8.02 (5H, m, aromatic-H). $^{13}\text{H-NMR}$ (CDCl_3): δ 20.57, 20.60 (CH_3), 38.40, 38.43 (C_4), 53.21 (OCH_3), 53.68, 53.83 (C_5), 53.88, 58.95 (C_2), 75.38 (C_3), 116.62 (CN), 128.63, 128.76, 129.81, 133.88 (aromatic-C), 165.41 (C=O). EIMS m/z : 288 (M^+). Anal. Calcd for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_4$: C, 62.49; H, 5.59; N, 9.72. Found: C, 62.38; H, 5.40; N, 9.66.

22: colorless oil. $[\alpha]^{21}_D -49.7^\circ$ (c 0.97, MeOH). IR (neat): 2220, 1732, 1603 cm^{-1} . $^1\text{H-NMR}$ (CDCl_3): δ 1.33 (3H, s, CH_3), 2.25 (1H, br s, $\text{C}_4\text{-H}_\beta$), 2.47–2.60 (1H, m, $\text{C}_4\text{-H}_\alpha$), 3.81 (3H, s, OCH_3), 4.21 (1H, br s, $\text{C}_5\text{-H}$), 5.05 (1H, d, $J=3.96$ Hz, $\text{C}_2\text{-H}$), 5.02–5.12 (1H, m, $\text{C}_3\text{-H}$), 7.43–8.20 (5H, m, aromatic-H). $^{13}\text{H-NMR}$ (CDCl_3): δ 20.83, 20.87 (CH_3), 35.57, 36.52 (C_4), 51.04, 51.16 (C_5), 51.52, 51.67 (C_2), 53.20 (OCH_3), 69.33, 70.04 (C_3), 115.10 (CN), 128.54, 128.66, 129.98, 133.91 (aromatic-C), 165.70 (C=O). HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_4$ (M^+): 288.1110. Found: 288.1098.

b) Preparation of *ent*-**21** and *ent*-**22**: The same treatment of *ent*-**19** (1.6 g, 5.5 mmol) as described for the preparation of **21** and **22** from **19** gave *ent*-**21** (1.05 g, 67%) as a more polar product and *ent*-**22** (0.26 g, 17%) as a less polar product.

ent-**21**: colorless needles, mp 87–88°C (ethyl acetate: petroleum ether). $[\alpha]^{25}_D +37.8^\circ$ (c 1.14, MeOH). The IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and mass spectra of this material were identical with those recorded for **21**.

ent-**22**: colorless oil. $[\alpha]^{25}_D +49.6^\circ$ (c 0.88, MeOH). The IR, $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and mass spectra of this material were identical with those recorded for **22**.

(2*R*,3*R*,5*R*)-3-Hydroxy-5-methyl-2-pyrrolidinecarboxylic acid [(2*R*,3*R*,5*R*)-1], Its (2*S*,3*R*,5*R*)-Isomer [(2*S*,3*R*,5*R*)-1], and (2*S*,3*S*,5*S*)-Isomer [(2*S*,3*S*,5*S*)-1]

a) Preparation of (2*R*,3*R*,5*R*)-**1**: A solution of **21** (0.7 g, 2.4 mmol) in 6M HCl (30 ml) was heated at 115°C for 24 h and then the solvent was evaporated *in vacuo*. The residue was dissolved in water (2 ml) and purified by Dowex 50W x 8 (50–100 mash) ion exchange column chromatography (water then 5% aqueous ammonia) to give (2*R*,3*R*,5*R*)-**1** (0.26 g, 75%) as a white solid. Recrystallization from 70% aqueous ethanol gave an analytical sample of (2*R*,3*R*,5*R*)-**1** as colorless needles, mp 252–253°C. $[\alpha]^{21}_D +17.8^\circ$ (c 0.88, H_2O); [lit.³ $[\alpha]_D +18^\circ$ (c 0.32, H_2O)]. IR (KBr): 3280, 2850–2200, 1636, 1570 cm^{-1} . $^1\text{H-NMR}$ (D_2O): δ 1.49 (3H, d, $J=6.60$ Hz, CH_3),

1.74 (1H, ddd, $J=14.28, 11.72, 4.39$ Hz, C4-H β), 2.18 (1H, ddd, $J=14.28, 5.87, 1.02$ Hz, C4-H α), 3.98–4.10 (2H, m, C2-, C5-H), 4.64–4.72 (1H, m, C3-H). $^{13}\text{H-NMR}$ (CDCl_3): δ 19.70 (CH_3), 41.96 (C4), 58.32 (C5), 72.16 (C2), 76.93 (C3), 174.38 (C=O). Anal. Calcd for $\text{C}_6\text{H}_{11}\text{NO}_3$: C, 49.64; H, 7.64; N, 9.65. Found: C, 49.40; H, 7.74; N, 9.56.

b) Preparation of (2*S*,3*R*,5*R*)-**1**: The same treatment of **22** (0.65 g, 2.2 mmol) as described for the preparation of (2*R*,3*R*,5*R*)-**1** from **21** gave (2*S*,3*R*,5*R*)-**1** (0.25 g, 78%) as colorless needles, mp 286–288°C (70% aqueous ethanol). $[\alpha]^{20}_{\text{D}} -85.1^\circ$ (c 0.70, H_2O). IR (KBr): 3332, 3100–2180, 1652, 1624, 1590, 1436, 1412 cm^{-1} . $^1\text{H-NMR}$ (D_2O): δ 1.43 (3H, d, $J=6.60$ Hz, CH_3), 1.91 (1H, ddd, $J=14.28, 11.73, 4.03$ Hz, C4-H β), 2.28 (1H, ddd, $J=14.28, 5.86, 1.72$ Hz, C4-H α), 4.05–4.16 (1H, m, C5-H), 4.24 (1H, d, $J=4.39$ Hz, C2-H), 4.70 (1H, t, $J=4.03$ Hz, C3-H). $^{13}\text{H-NMR}$ (CDCl_3): δ 19.62 (CH_3), 44.02 (C4), 57.68 (C5), 69.59 (C2), 73.94 (C3), 173.26 (C=O).

c) Preparation of (2*S*,3*S*,5*S*)-**1** from *ent*-**21**: The same treatment of *ent*-**21** (0.80 g, 2.8 mmol) as described for the preparation of (2*R*,3*R*,5*R*)-**1** from **21** gave (2*S*,3*S*,5*S*)-**1** (0.28 g, 70%) as colorless needles, mp 252–253°C [lit.³ mp 247–249°C (decomp.)]. $[\alpha]^{21}_{\text{D}} -17.6^\circ$ (c 0.80, H_2O), [lit.³ $[\alpha]_{\text{D}} -17^\circ$ (c 0.50, H_2O)]. The IR, $^1\text{H-NMR}$, and $^{13}\text{C-NMR}$ spectra of this material were identical with those recorded for (2*R*,3*R*,5*R*)-**1**.

Acknowledgement: This work was financially supported in part by the Special Research Fund of Hokuriku University.

References

1. Katz, E.; Mason, K. T.; Mauger, A. B. *Biochem. Biophys. Res. Commun.* **1975**, 63, 502–508.
2. Mauger, A. B.; Stuart, O. A.; Katz, E.; Mason, K. T. *J. Org. Chem.* **1977**, 42, 1000–1005.
3. Fushiya, S.; Chiba, H.; Otsubo, A.; Nozoe, S. *Chem. Lett.* **1987**, 2229–2232.
4. a) Tanaka, K.; Sawanishi, H. *Tetrahedron: Asymmetry* **1995**, 6, 1641–1656. b) Tanaka, K.; Iwabuchi, H.; Sawanishi, H. *Tetrahedron: Asymmetry* **1995**, 6, 2271–2279. c) Tanaka, K.; Suzuki, H.; Sawanishi, H. *Heterocycles* **1996**, 43, 205–219.
5. a) Thaning, M.; Wistrand, L-G. *Acta. Chem. Scand.* **1989**, 43, 290–295. b) Corey, E. J.; Yuen, P. W.; Hannon, F. J.; Wierda, D. A. *J. Org. Chem.* **1990**, 55, 784–786. c) Langlois, N.; Rojas, A. *Tetrahedron* **1993**, 49, 77–82. d) Katoh, T.; Nagata, Y.; Kobayashi, Y.; Arai, K.; Minami, J.; Terashima, S. *Tetrahedron* **1994**, 50, 6221–6238. e) Cotton, R.; Johnstone, A. N. C.; North, M. *Tetrahedron* **1995**, 51, 8525–8544. f) Langlois, N.; R-Rousseau, A.; Decavallas, O. *Tetrahedron: Asymmetry* **1996**, 7, 1095–1100. g) Panday, S-K.; Langlois, N. *Synth. Commun.* **1997**, 27, 1373–1384.
6. a) Shono, T.; Fujita, T.; Matsumura, Y. *Chem. Lett.* **1991**, 81–84. b) Matsumura, Y.; Tomita, T. *Tetrahedron Lett.* **1994**, 35, 3737–3740.
7. Tanaka, K.; Sawanishi, H. *Tetrahedron: Asymmetry* **1998**, 9, 71–77.
8. Rosen, T.; Chu, D. T. W.; Lico, I. M.; Fernandes, P. B.; Marsh, K.; Shen, L.; Cepa, V. G.; Pernet, A. G. *J. Med. Chem.* **1988**, 31, 1598–1611.
9. Li, H.; Sakamoto, T.; Kato, M.; Kikugawa, Y. *Synth. Commun.* **1995**, 25, 4045–4052.

10. a) Kozikowski, A. P.; Sorgi, K. L.; *Tetrahedron Lett.* **1982**, 23, 2281-2284. b) Lewis, M. D.; Cha, J. K.; Kishi, Y. *J. Am. Chem. Soc.* **1982**, 104, 4976-4978. c) Thaning, M.; Wistrand, L. G. *Helv. Chim. Acta.* **1986**, 69, 1711-1717.
11. Stevens, R. V. *Acc. Chem. Res.* **1984**, 17, 289.
12. Williams, M. A.; Rapoport, H. *J. Org. Chem.* **1994**, 59, 3616-3625 and references cited therein.
13. Mitsunobu, O. *Synthesis* **1981**, 1-28.